Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010318.pdf
0001558370-16-010318.rtf
0001558370-16-010318.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010326.pdf
0001558370-16-010326.rtf
0001558370-16-010326.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010336.pdf
0001558370-16-010336.rtf
0001558370-16-010336.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010300.pdf
0001558370-16-010300.rtf
0001558370-16-010300.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-16-032094.pdf
0001179110-16-032094.rtf
0001179110-16-032094.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-032096.pdf
0001179110-16-032096.rtf
0001179110-16-032096.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010074.pdf
0001558370-16-010074.rtf
0001558370-16-010074.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-009879.pdf
0001558370-16-009879.rtf
0001558370-16-009879.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-16-009951.pdf
0001558370-16-009951.rtf
0001558370-16-009951.xls
EX-101.INS - EX-101.INS
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-031138.pdf
0001179110-16-031138.rtf
0001179110-16-031138.xls